Table 1. Sources of patient's derived melanoma cells.
| Melanoma | Gender/age | Stage/site | BRAF status | PTEN |
| WW165 | F/62 | Primary melanoma, 2.25 mm | V600K (GTG->AAG) | WT, Present* |
| YUMAC | M/68 | IV, Soft tissue metastasis, right thigh | V600K (GTG->AAG) | WT, Null (no protein) |
| YUGEN8 | F/44 | IV, Brain metastasis | V600E (GTG->GAG) | Null (no gene transcripts) |
| YUSAC2 | M/57 | IV, Soft tissue metastasis, left neck | V600E (GTG->GAG) | WT/LOH (Present) |
| YUSIT1 | M/67 | Metastatic melanoma | V600K (GTG->AAG) | WT (Present) |
| YULAC | F/66 | IV, Soft tissue metastasis, neck | V600K (GTG->AAG) | P38S/LOH (C1143T) |
| YURIF | M/53 | IV, Soft tissue metastasis, right thigh | V600K (GTG->AAG) | LOH Present |
| 501 mel | Not known | Lymph node metastasis | V600E (GTG->GAG) | WT, Present |
*
Present indicates normal levels of gene transcripts and protein expression compared to normal melanocytes. There was no induction of PTEN mRNA after Aza treatment.